Cellectis (CLLS) Non-Current Debt (2014 - 2026)
Cellectis (CLLS) posted quarterly Non-Current Debt of $67.5 million for Q1 2026, up 32.25% year-over-year from $51.0 million in Q1 2025, and down 8.8% quarter-over-quarter from $74.0 million in Q4 2025.
Cellectis (CLLS) Non-Current Debt (2014 - 2026) Analysis & Trends
Cellectis' Non-Current Debt history runs 12 years deep, the most recent figure standing at $67.5 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 32.25% year-over-year to $67.5 million; the TTM figure through Mar 2026 stood at $67.5 million (up 32.25% YoY), while the FY2025 annual figure was $74.0 million, up 45.46% from the prior year.
- Non-Current Debt for Q1 2026 stood at $67.5 million, down from $74.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $74.0 million in Q4 2025, with the low at $5.9 million in Q2 2022.
- The 5-year median for Non-Current Debt is $50.9 million (2024), against an average of $44.5 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt tumbled 74.87% in 2022, then surged 582.54% in 2023.
- Cellectis' Non-Current Debt stood at $20.5 million in 2022, then soared by 139.27% to $49.1 million in 2023, then grew by 3.58% to $50.9 million in 2024, then surged by 45.46% to $74.0 million in 2025, then retreated by 8.8% to $67.5 million in 2026.
- Business Quant data shows CLLS's Non-Current Debt at $67.5 million in Q1 2026, $74.0 million in Q4 2025, and $63.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 67.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.50 Mn |
| Dec 31, 2025 | 74.01 Mn |
| Sep 30, 2025 | 63.40 Mn |
| Jun 30, 2025 | 55.86 Mn |
| Mar 31, 2025 | 51.04 Mn |
| Dec 31, 2024 | 50.88 Mn |
| Sep 30, 2024 | 61.58 Mn |
| Jun 30, 2024 | 58.35 Mn |
| Mar 31, 2024 | 62.62 Mn |
| Dec 31, 2023 | 49.13 Mn |
| Sep 30, 2023 | 43.25 Mn |
| Jun 30, 2023 | 40.27 Mn |
| Mar 31, 2023 | 19.63 Mn |
| Dec 31, 2022 | 20.53 Mn |
| Sep 30, 2022 | 14.70 Mn |
| Jun 30, 2022 | 5.90 Mn |
| Mar 31, 2022 | 18.35 Mn |
| Dec 31, 2021 | 20.03 Mn |
| Sep 30, 2021 | 22.77 Mn |
| Jun 30, 2021 | 23.48 Mn |